These data indicate that the selective EP4 agonist L-902,688 attenuates RV cardiac fibrosis by suppressing EndMT and that increasing EP4 signaling in the RV might be an approach to reducing RV fibrosis and improving RV function in patients with pulmonary hypertension. This evidence concerns the gene PTGER4 and pulmonary arterial hypertension.